Volume 5, Issue 1 (Winter 2016)                   J Occup Health Epidemiol 2016, 5(1): 38-44 | Back to browse issues page


XML Print


1- Dept. of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
2- Dept. of Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
3- Molecular Medicine Research Center and Dept. of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
4- Molecular Medicine Research Center and Dept. of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
5- Molecular Medicine Research Center and Dept. of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. , hajizadehus@yahoo.com
Article history
Received: 2016/06/20
Accepted: 2016/10/18
ePublished: 2017/01/25
Abstract:   (7073 Views)

Background: Chemerin is and adipokine produced and secreted by adipose tissue and is associated with functions such as insulin resistance, inflammation, and blood pressure regulation. The purpose of the present study was the determination of serum chemerin level in an Iranian population with metabolic syndrome and its comparison with healthy individuals.

Materials and Methods: The study subjects consisted of 31 individuals with metabolic syndrome and 25 healthy individuals (control group). Serum chemerin level was measured and its relationship with indices of metabolic syndrome, obesity, and insulin resistance was determined. The collected data were analyzed using independent two-sample t-test and the Pearson correlation coefficient in SPSS software.

Results: Serum chemerin level was significantly higher in the metabolic syndrome group compared to the control group (P = 0.009). The mean of the measured indices of BMI (P < 0.001), waist circumference (P < 0.001), systolic blood pressure (P = 0.001), diastolic blood pressure (P < 0.001), insulin resistance (P = 0.001), and triglyceride (P < 0.001) was significantly higher in the metabolic syndrome group compared to the control group. However, HDL level was significantly higher in the control group compared to the metabolic syndrome group (P = 0.007).

Conclusions: Serum chemerin level was higher among patients with metabolic syndrome compared to healthy individuals. Thus, it can be concluded that serum chemerin level measurement can be effective in the diagnosis of this syndrome and determination of appropriate treatment methods.

Full-Text [PDF 479 kb]   |   Full Text (HTML)   (1986 Downloads)    

References
1. Fatima SS, Bozaoglu K, Rehman R, Alam F, Memon AS. Elevated chemerin levels in Pakistani men: an interrelation with metabolic syndrome phenotypes. PLoS One 2013; 8(2):e57113.
2. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010:802078.
3. Wang D, Yuan GY, Wang XZ, Jia J, Di LL, Yang L, et al. Plasma chemerin level in metabolic syndrome. Genet Mol Res 2013; 12(4):5986-91.
4. Ali TM, Al Hadidi K. Chemerin is associated with markers of inflammation and predictors of atherosclerosis in Saudi subjects with metabolic syndrome and type 2 diabetes mellitus. Beni-Suef University Journal of Basic and Applied Sciences 2013; 2(2):86-95.
5. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014:943162.
6. Emanuela F, Grazia M, Marco DR, Maria Paola L, Giorgio F, Marco B. Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012; 2012:476380.
7. Delavari A, Forouzanfar MH, Alikhani S, Sharifian A, Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009; 32(6):1092-7.
8. Osman MM, El-Mageed AIA, El-Hadidi E, Shahin RSK, Mageed NAAA. Clinical utility of serum chemerin as a novel marker of metabolic syndrome and type 2 diabetes mellitus. Life science journal 2012; 9(2):1098-108.
9. Mattern A, Zellmann T, Beck‐Sickinger AG. Processing, signaling, and physiological function of chemerin. IUBMB Life 2014; 66(1):19-26.
10. Li Y, Shi B, Li S. Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis. PLoS One 2014; 9(12):e113915.
11. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013; 98(3):E514-7.
12. Coimbra S, Brandão Proença J, Santos-Silva A, Neuparth MJ. Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int 2014; 2014:701915.
13. Elsebai AA, Saad WE, Mahdy MM. Serum chemerin and beta 2-microglobulin in type 2 diabetes: assessment of diabetic nephropathy. Life science journal 2014; 11(8):992-1000.
14. Aksan G, İnci S, Nar G, Soylu K, Gedikli Ö, Yüksel S, et al. Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome. Int J Clin Exp Med 2014; 7(12):5461-8.
15. Koç F, Tokaç M, Kocabaş V, Kaya C, Büyükbaş S, Erdem S, et al. Ghrelin, resistin and leptin levels in patients with metabolic syndrome. European Journal of General Medicine 2011; 8(2):92-7.
16. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism 2008; 57(4):494-501.
17. Lin CC, Liu CS, Li CI, Lin WY, Lai MM, Lin T, et al. The relation of metabolic syndrome according to five definitions to cardiovascular risk factors-a population-based study. BMC Public Health 2009; 9:484.
18. Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr Med Res Opin 2004; 20(3):295-304.
19. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett. 2008; 582(5):573-8
20. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94(8):3085-8.
21. Chu SH, Lee MK, Ahn KY, Im JA, Park MS, Lee DC, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012; 7(4):e34710.
22. Sadashiv, Tiwari S, Paul BN, Kumar S, Chandra A, Dhananjai S, et al. Over expression of resistin inadipose tissue of the obese induces insulin resistance. World J Diabetes 2012; 3(7):135-41.

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.